Related Experiment Video
Updated: Oct 15, 2025

05:00
Author Spotlight: Enhancing Multicolor Fluorescence Localization in Lung Carcinoma Sample
Published on: November 21, 2023
2.1K
TNF Patterns and Tumor Microenvironment Characterization in Head and Neck Squamous Cell Carcinoma
Qian Long1, Chunyu Huang1, Qi Meng1
1Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Frontiers in Immunology
|October 25, 2021
Summary
This study analyzes the Tumor Necrosis Factor (TNF) family in head and neck squamous cell carcinoma (HNSCC). We identified two HNSCC subtypes and developed a risk score predicting survival and immune infiltration for potential immunotherapy applications.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Head and neck squamous cell carcinoma (HNSCC) is a complex disease with a highly immunosuppressive tumor microenvironment.
- The Tumor Necrosis Factor (TNF) family is critical for immune cell function, but its role in HNSCC requires systematic investigation.
- Understanding TNF expression patterns is essential for developing targeted therapies.
Purpose of the Study:
- To systematically analyze the expression patterns of the TNF family in HNSCC.
- To identify distinct HNSCC subtypes based on TNF gene expression.
- To develop a risk scoring system for predicting clinical outcomes and immune characteristics.
Main Methods:
- Utilized transcriptional profile data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets for HNSCC.
- Employed unsupervised clustering to identify TNF expression patterns and patient subtypes.
- Constructed a risk score using Principal Component Analysis (PCA) based on TNF gene expression.
Main Results:
- Identified two distinct HNSCC subtypes with unique clinical and immune profiles based on TNF family gene expression.
- Developed a novel risk scoring system derived from TNF gene expression patterns.
- Demonstrated that the risk score effectively predicts overall survival, clinical characteristics, and immune cell infiltration.
Conclusions:
- The developed risk score is a reliable predictor for HNSCC patient outcomes.
- This TNF-based risk score holds potential as a valuable biomarker for guiding HNSCC immunotherapy strategies.
- Further research into TNF family roles can enhance precision medicine approaches for HNSCC.

